Innate Pharma Stock Earnings Reports

Innate Pharma has strategically refocused to prioritize three clinical-stage assets: IPH4502 (a differentiated Nectin-4 exatecan ADC), lacutamab (anti-KIR3DL2 for CTCL and PTCL) and monalizumab (partnered with AstraZeneca in Phase III PACIFIC-9). IPH4502 showed preclinical activity in enfortumab vedotin (EV)-resistant and low/heterogeneous Nectin‑4 tumors, is in a Phase I dose-escalation expected to complete enrollment by Q1 2026, and preliminary clinical data are expected in H1 2026 (~50–60 patients anticipated). Lacutamab has FDA Breakthrough Therapy designation for relapsed/refractory Sézary syndrome, long-duration responses in TELLOMAK Phase II (e.g., median DOR 25.6 months in Sézary), a near-final Phase III protocol after regulator input, and plans to initiate confirmatory Phase III after securing financing or a partner with potential accelerated approval in 2027. Monalizumab remains a meaningful value driver via AstraZeneca (deal up to $1.275B; €450M received to date), with PACIFIC-9 fully recruited and primary completion in H1 2026 (data expected H2 2026). The company will rightsize the organization (CSO Eric Vivier returning to academia but remaining an R&D adviser; COO Yannis Morel assuming CSO responsibilities) and focus R&D/external spend on the prioritized assets. Financially, H1 2025 revenue was €4.9M, operating expenses €30.3M (R&D €20.5M), cash of €70.4M at June 30, 2025, and a reported cash runway into the end of Q3 2026 (restructuring effects included). NK‑cell/ANKET programs are deprioritized but not terminated; decisions will depend on upcoming clinical readouts (e.g., IPH6501 data expected late 2025/early 2026). Key near-term catalysts: IPH4502 preliminary data H1 2026, lacutamab Phase III protocol finalization and financing/partnering decision (trial start target 2026/2027), and monalizumab PACIFIC-9 readout H2 2026.